Rubedo Life Sciences, a Sunnyvale, CA-based biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases, closed a $40M Series A financing round.
The round was led by Khosla Ventures and Ahren Innovation Capital, with participation from Hevolution, R42, Modi Ventures, Cerigo Investments, Shanda Group, Refactor Capital, LongeVC, Italian Angels for Growth (IAG), and other investors.
The company intends to use the funds to advance its lead candidate RLS-1496 in chronic atopic dermatitis and chronic psoriasis, which will be entering Phase 1 studies.
Led by CEO Marco Quarta, and Chief Business Officer Ali Siam, Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Its proprietary ALEMBIC™ drug discovery platform has engineered novel small molecules designed to selectively target various types of senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders.
The company is developing its lead candidate RLS-1496 in chronic atopic dermatitis and chronic psoriasis, which will be entering Phase 1 studies.
Rubedo is also developing additional therapies that selectively target senescent cells in pulmonary diseases with significant unmet medical need, such as idiopathic pulmonary fibrosis (IPF), with a program recipient of a substantial CIRM grant last year.
FinSMEs
22/04/2024